What conditions are steroids commonly prescribed for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Common Medical Conditions for Steroid Prescription

Steroids are commonly prescribed for a wide range of inflammatory, autoimmune, and allergic conditions where their potent anti-inflammatory and immunosuppressive effects can significantly reduce morbidity and mortality.

Endocrine Disorders

  • Primary or secondary adrenocortical insufficiency 1
  • Acute adrenocortical insufficiency 1
  • Congenital adrenal hyperplasia 1
  • Nonsuppurative thyroiditis 1
  • Hypercalcemia associated with cancer 1

Rheumatologic Conditions

  • Rheumatoid arthritis, including juvenile rheumatoid arthritis 1, 2
  • Adult-onset Still's disease (AOSD) - most patients (88%) require prednisone at some point during their disease course 2
  • Acute and subacute bursitis 1
  • Ankylosing spondylitis 1
  • Psoriatic arthritis 1
  • Acute gouty arthritis 1
  • Post-traumatic osteoarthritis 1
  • Synovitis of osteoarthritis 1

Collagen Vascular Diseases

  • Systemic lupus erythematosus 1, 2
  • Acute rheumatic carditis 1

Dermatologic Conditions

  • Severe psoriasis 1
  • Pemphigus 1
  • Severe erythema multiforme (Stevens-Johnson Syndrome) 1
  • Exfoliative dermatitis 1
  • Bullous dermatitis herpetiformis 1
  • Severe seborrheic dermatitis 1
  • Atopic dermatitis - topical steroids are used for short-term treatment 2

Allergic States

  • Bronchial asthma 1, 3
  • Seasonal or perennial allergic rhinitis 1
  • Drug hypersensitivity reactions 1
  • Serum sickness 1
  • Contact dermatitis 1
  • Atopic dermatitis 1
  • Urticarial transfusion reactions 1
  • Acute noninfectious laryngeal edema 1

Ophthalmologic Conditions

  • Dry eye disease - topical steroids for short-term use in moderate to severe cases 2, 4
  • Allergic conjunctivitis 1
  • Keratitis 1
  • Iritis and iridocyclitis 1
  • Optic neuritis 1
  • Herpes zoster ophthalmicus 1
  • Allergic corneal marginal ulcers 1

Respiratory Diseases

  • Symptomatic sarcoidosis 1
  • Berylliosis 1
  • Loeffler's syndrome not manageable by other means 1
  • Aspiration pneumonitis 1
  • Fulminating or disseminated pulmonary tuberculosis (with appropriate anti-TB therapy) 1

Gastrointestinal Diseases

  • Ulcerative colitis (systemic therapy) 1
  • Regional enteritis (systemic therapy) 1

Hematologic Disorders

  • Acquired (autoimmune) hemolytic anemia 1
  • Idiopathic thrombocytopenic purpura in adults 1
  • Secondary thrombocytopenia in adults 1
  • Erythroblastopenia (RBC anemia) 1

Neurological Conditions

  • Cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury 1
  • Tuberculosis meningitis with subarachnoid block when used with appropriate anti-TB therapy 1

Otolaryngologic Conditions

  • Sudden sensorineural hearing loss (SSNHL) - oral prednisone at 1 mg/kg/day (max 60 mg daily) for 10-14 days 2
  • Hoarseness - not routinely recommended due to potential adverse effects 2

Special Considerations and Cautions

Potential Adverse Effects

  • Lipodystrophy, hypertension, and cardiovascular disease 2
  • Osteoporosis and avascular necrosis 2
  • Impaired wound healing and myopathy 2
  • Cataracts and other ophthalmologic disorders 2
  • Increased risk of infections 2
  • Mood disorders and hormonal changes 2
  • Hyperglycemia and diabetes 2
  • Adrenal suppression 2

Mechanism of Action

  • Glucocorticoids bind to cytoplasmic receptors, dimerize and translocate to the nucleus 5
  • They inhibit inflammatory gene expression by interacting with transcription factors like nuclear factor-kappa B 5
  • This results in suppression of multiple inflammatory mediators and pathways 5

Treatment Resistance

  • Some patients with chronic inflammatory diseases may develop corticosteroid insensitivity 6
  • This phenomenon is seen in approximately 5% of asthma patients and also occurs in rheumatoid arthritis and inflammatory bowel disease 6

Route of Administration Considerations

  • Inhaled steroids are preferred over oral steroids for chronic asthma when possible 3
  • A daily dose of prednisolone 7.5-10 mg appears equivalent to moderate-high dose inhaled corticosteroids 3
  • Intra-articular or soft tissue injections may be used for localized inflammatory conditions 1
  • Topical steroids are preferred for dermatological and ophthalmological conditions when appropriate 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Inhaled vs oral steroids for adults with chronic asthma.

The Cochrane database of systematic reviews, 2000

Guideline

Lifitegrast 5% Solution for Dry Eye Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Anti-inflammatory actions of glucocorticoids: molecular mechanisms.

Clinical science (London, England : 1979), 1998

Research

Corticosteroid-insensitive asthma: molecular mechanisms.

The Journal of endocrinology, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.